WO2013082515A2 - Aptamères d'acides nucléiques dirigés sur des récepteurs de surface et procédés d'utilisation - Google Patents

Aptamères d'acides nucléiques dirigés sur des récepteurs de surface et procédés d'utilisation Download PDF

Info

Publication number
WO2013082515A2
WO2013082515A2 PCT/US2012/067423 US2012067423W WO2013082515A2 WO 2013082515 A2 WO2013082515 A2 WO 2013082515A2 US 2012067423 W US2012067423 W US 2012067423W WO 2013082515 A2 WO2013082515 A2 WO 2013082515A2
Authority
WO
WIPO (PCT)
Prior art keywords
aptamer
trkb
nucleic acid
agonist
cell
Prior art date
Application number
PCT/US2012/067423
Other languages
English (en)
Other versions
WO2013082515A3 (fr
Inventor
James O. Mcnamara
Yangzhong Huang
Bin Gu
James O. MCNAMARAII
Paloma H. Giangrande
Frank Jeyson HERNANDEZ
Katie R. FLENKER
Original Assignee
Duke University
University Of Iowa Research Foundation Iowa Centers For Enterprise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, University Of Iowa Research Foundation Iowa Centers For Enterprise filed Critical Duke University
Publication of WO2013082515A2 publication Critical patent/WO2013082515A2/fr
Publication of WO2013082515A3 publication Critical patent/WO2013082515A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un aptamère agoniste, C4-3, qui se lie au domaine extracellulaire du récepteur de kinase B liée à la tyrosine (TrkB) avec une affinité élevée, présente une puissante activité agoniste partielle TrkB et des effets neuroprotecteurs dans des neurones corticaux cultivés, et active TrkB lors d'une perfusion dans l'hippocampe. L'aptamère selon l'invention est également utile pour le traitement d'un ou de troubles neurologiques ou neuropsychiatriques. L'invention décrit également l'approche de sélection d'aptamère à base de cellule pour l'identification d'agonistes à base d'aptamère pour une diversité de récepteurs de signalisation de surface cellulaire.
PCT/US2012/067423 2011-12-02 2012-11-30 Aptamères d'acides nucléiques dirigés sur des récepteurs de surface et procédés d'utilisation WO2013082515A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566120P 2011-12-02 2011-12-02
US61/566,120 2011-12-02

Publications (2)

Publication Number Publication Date
WO2013082515A2 true WO2013082515A2 (fr) 2013-06-06
WO2013082515A3 WO2013082515A3 (fr) 2013-08-15

Family

ID=48536242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/067423 WO2013082515A2 (fr) 2011-12-02 2012-11-30 Aptamères d'acides nucléiques dirigés sur des récepteurs de surface et procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2013082515A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108265036A (zh) * 2018-01-26 2018-07-10 山东大学齐鲁医院 一种沉默t1蛋白的重组病毒及其构建方法与应用
CN110384712A (zh) * 2019-07-16 2019-10-29 南方医科大学 核酸适配子在制备治疗阿尔茨海默氏病药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059138A1 (fr) * 2003-12-16 2005-06-30 Agency For Science, Technology And Research Procedes et composes permettant de modifier le degre de contamination microbienne d'un virus de l'hepatite
US20100076060A1 (en) * 2005-09-15 2010-03-25 Duke University Aptamers as agonists
US20100291593A1 (en) * 2007-07-13 2010-11-18 Powell William C Method of identifying diagnostic reagents
US20110038865A1 (en) * 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059138A1 (fr) * 2003-12-16 2005-06-30 Agency For Science, Technology And Research Procedes et composes permettant de modifier le degre de contamination microbienne d'un virus de l'hepatite
US20100076060A1 (en) * 2005-09-15 2010-03-25 Duke University Aptamers as agonists
US20110038865A1 (en) * 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
US20100291593A1 (en) * 2007-07-13 2010-11-18 Powell William C Method of identifying diagnostic reagents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG, YANG ZHONG ET AL.: 'RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB.' MOL PHARMACOL. vol. 82, no. 4, 29 June 2012, pages 623 - 635 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108265036A (zh) * 2018-01-26 2018-07-10 山东大学齐鲁医院 一种沉默t1蛋白的重组病毒及其构建方法与应用
CN110384712A (zh) * 2019-07-16 2019-10-29 南方医科大学 核酸适配子在制备治疗阿尔茨海默氏病药物中的应用

Also Published As

Publication number Publication date
WO2013082515A3 (fr) 2013-08-15

Similar Documents

Publication Publication Date Title
JP7021320B2 (ja) 治療用分子を選択する方法
KR102021626B1 (ko) Ngf에 대한 압타머 및 그의 용도
Fernández et al. TLR4-binding DNA aptamers show a protective effect against acute stroke in animal models
TWI505833B (zh) 針對β－ＮＧＦ之適體與彼等在治療涉及β－ＮＧＦ之疾病及異常之用途
JP2022532169A (ja) オリゴヌクレオチド組成物及びその使用方法
Huang et al. RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB
CN103372218B (zh) 自身免疫性疾病相关的microRNA及其应用
CN108064227A (zh) 用于调节τ蛋白表达的组合物
RU2699706C2 (ru) Вещества и способы модуляции заживления сухожилий
US20150291954A1 (en) Organic compositions to treat beta-catenin-related diseases
WO2013186857A1 (fr) Aptamère de fgf2 et son utilisation
JP2013539456A (ja) ＶＥＧＦＡをターゲティングするｓｉＲＮＡ及びｉｎｖｉｖｏ治療のための方法
US20220372492A1 (en) Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
US20160040126A1 (en) Regulation of differentiation into dopaminergic neurons by metalloprotease
US20170355997A1 (en) Methods and compositions for treating or preventing pruritis
Moazami et al. Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system
WO2005092306A1 (fr) Procedes et compositions pour moduler la tolerance aux opioides et la douleur chronique
KR20150047513A (ko) 눈 증상의 치료 및/또는 예방을 위한 방법 및 조성물에서 sirna 및 이들의 용도
US10016424B2 (en) Method and pharmaceutical composition for use in the treatment of epilepsy
WO2013082515A2 (fr) Aptamères d'acides nucléiques dirigés sur des récepteurs de surface et procédés d'utilisation
JP2010502640A (ja) ｍＴＯＲシグナル伝達を調節する組成物および方法
Twede et al. Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor
KR102394676B1 (ko) Fgf2에 대한 압타머 및 그의 사용
EP2897633B1 (fr) Traitement de la douleur par inhibition de la déubiquitinase usp5
Alhajlah et al. Overexpression of Reticulon 3 enhances CNS axon regeneration and functional recovery after injury

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12852956

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12852956

Country of ref document: EP

Kind code of ref document: A2